<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> is characterized by mild <z:hpo ids='HP_0008282'>unconjugated hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The molecular basis of this syndrome usually concerns an additional <z:chebi fb="0" ids="47885">dinucleotide</z:chebi> insertion (TA) in the A(TA)(n)<z:chebi fb="2" ids="32497">TAA</z:chebi> configuration residing in the promoter region of the UGT1 A1 gene </plain></SENT>
<SENT sid="2" pm="."><plain>This configuration may vary in length; the "n" represents the different number of TA repeats </plain></SENT>
<SENT sid="3" pm="."><plain>The homozygosity A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi>/A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi> is involved in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In many cases of patients with <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> and <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> considerable variation in <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels is observed </plain></SENT>
<SENT sid="5" pm="."><plain>In this study we investigated the contribution of the A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi>/A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi> genotype in the variable unconjugated serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in 31 Greek patients with <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> and 27 Greek compound heterozygotes for <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta thalassemia</z:e> and sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of the A(TA)(n)<z:chebi fb="2" ids="32497">TAA</z:chebi> configuration in the promoter region of the latter patients showed that those who were carrying the homozygosity A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi>/A(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi> had higher levels of unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that the coexistence of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> in patients with <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> and <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> may be the cause of the elevated values of unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi>, reducing the possibility of excessive <z:mp ids='MP_0010163'>hemolysis</z:mp> in these patients </plain></SENT>
</text></document>